Truist Boosts Boston Scientific (BSX) Price Target After Strong Quarter

Boston Scientific Corporation (NYSE:BSX) ranks among the best medical stocks to buy according to analysts. On July 25, Truist Securities maintained its Buy rating on Boston Scientific Corporation (NYSE:BSX) while increasing its price target from $120 to $125. The price target upgrade comes after what Truist calls a “strong quarter with multiple tailwinds supporting higher estimates.”

The firm noted that Boston Scientific Corporation (NYSE:BSX) produced a broad-based earnings beat, with its PFA and accelerated Watchman growth divisions showing excellent results. According to Truist, challenges in the TAVR (Transcatheter Aortic Valve Replacement) market should be more than compensated by Boston Scientific’s quarterly results, sustained momentum, and improved tariff outlook.

In the second half of 2025, the firm expects “beat and raises” and stated confidence that Boston Scientific Corporation (NYSE:BSX) can continue to produce upside to its now-higher estimate.

Boston Scientific Corporation (NYSE:BSX) is a global leader in the manufacture of medical devices, including stents, brain stimulation systems, heart monitors, and catheters.

While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.